Clinical Trial Finder

Inclusion Criteria:

For rheumatoid arthritis:

• - Moderate-to-severely active RA as defined by the presence of ≥4 swollen joints (based on 28 joint count) and ≥4 tender joints (based on 28 joint count) at Screening and Day 1.

• - Documentation of ≥1 of the following: 1.

Positive test results for rheumatoid factor or anti-citrullinated peptide antibodies at Screening, OR. 2. Previous radiographs with bony erosions in hands or feet consistent with RA.

• - Inadequate response (defined as signs and symptoms of persistently active disease, loss of response, or intolerance) to one of the following: 1.

≥1 csDMARD treatment; OR. 2. 1 bDMARD or 1 tsDMARD treatment (a total of 2 bDMARDs and/or tsDMARDs is exclusionary) For axial spondyloarthritis:

• - Moderate-to-severely active axSpA defined by BOTH of the following at Screening AND Day 1: 1.

BASDAI ≥4, AND. 2. Back pain ≥4 (from BASDAI Item 2)

• - hsCRP greater than the ULN per the central laboratory at Screening - Inadequate response (defined as signs and symptoms of persistently active disease, loss of response, or intolerance) to one of the following: 1.

2 different NSAIDs given at the maximum tolerated dose for ≥4 weeks or intolerant to or has a contraindication to NSAID therapy; OR. 2. 1 bDMARD (anti-TNF or anti-IL-17) or 1 tsDMARD treatment at an approved dose for ≥12 weeks (a total of 2 bDMARDs and/or tsDMARDs is exclusionary) For psoriatic arthritis:

• - Day 1 TJC ≥3 out of 68 and SJC ≥3 out of 66 (dactylitis counts as 1 joint each) - ≥1 active plaque psoriasis lesion and/or a documented history of psoriasis.

• - In adequate response (defined as signs and symptoms of persistently active disease, loss of response, or intolerance) to one of the following: 1.

≥1 NSAID treatment; AND. 2. ≥1 csDMARD treatment; OR. 3. 1 bDMARD or 1 tsDMARD treatment (a total of 2 bDMARDs and/or tsDMARDs is exclusionary)

Exclusion Criteria:

• - Inadequate response to ≥2 or more bDMARDs and/or tsDMARDs.

- Other autoimmune, rheumatologic, inflammatory diseases or pain-amplification syndromes that might confound the evaluations of efficacy of SPY072

The basket study comprises of substudies in rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatric arthritis (PsA) as follows:

• - RA substudy: Moderately to severely active RA despite treatment with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), biologic disease modifying anti-rheumatic drugs (bDMARDs), or targeted synthetic disease-modifying anti-rheumatic drugs (tsDMARDs) - axSpA substudy: Moderately to severely active axSpA despite treatment with non-steroidal anti-inflammatory drugs (NSAIDS), bDMARDs, or tsDMARDs.

- PsA substudy: Moderately to severely active PsA despite treatment with NSAIDs, csDMARDs, bDMARDs, or tsDMARDs

Arms

Experimental: Rheumatoid Arthritis, Dose Regimen 1

Participants will receive double-blind dosing regimen 1 of SPY072

Experimental: Rheumatoid Arthritis, Dose Regimen 2

Participants will receive double-blind dosing regimen 2 of SPY072

Experimental: Psoriatic Arthritis

Participants will receive double-blind dose of SPY072

Experimental: Axial Spondyloarthritis

Participants will receive double-blind dose of SPY072

Placebo Comparator: Rhematoid Arthritis Placebo

Participants will receive matching placebo

Placebo Comparator: Psoriatic Arthritis Placebo

Participants will receive matching placebo

Placebo Comparator: Axial Spondyloarthritis Placebo

Participants will receive matching placebo

Interventions

Drug: - SPY002-072

Experimental

Drug: - Placebo

Matching Placebo